Track record · closed signal

Abbott Laboratories (ABT) — closed signal from April 7, 2026

Partial Published before the outcome was known, scored automatically when the window closed on July 6, 2026 — -6.1% at the close.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted
$101.85 Published $115.09 Target $95.63 Window close $103.84 Peak
$99.00 – $103.00Entry zone — fair-value band
$101.85Published — price the day we called it
$115.09Target — the price the thesis aimed for
$103.84Peak — highest point inside the window, not a realized return
$95.63Window close — end-of-window price, context only

What happened

Partial

Reached 15% of the predicted growth at its peak, without hitting the target.

At window close
-6.1%
realized, from the publication price to the last close inside the window
Peak gain
+1.9%
peak, from the publication price — not a realized return
S&P 500, same window
+14.3%
SPY over the identical days, dividend-adjusted
Window close
$95.63
last close inside the window, ended July 6, 2026
Peak price
$103.84
peak on April 8, 2026 — not a realized return
Days to target
—

The thesis — published April 7, 2026

Predicted growth
+13%
over the measurement window
Target price
$115.09
the price the thesis aimed for
Entry zone
$99.00 – $103.00
the fair-value band we waited for
Price at publication
$101.85
published April 7, 2026
Confidence
76%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Abbott looks like a defensive rebound candidate for the next 0-3 months. Shares fell below a recent short-term trend, but the company's business continues to run steadily. Recent analyst attention brings focus without heavy crowding. The trade appears more attractive now, though it still needs signs that selling has calmed before confirmation.

Primary drivers

  • Medical and nutrition products sell in steadier demand
  • Fresh analyst attention brings renewed focus without crowding
  • Shares moved into a cheaper, lower-price zone after the pullback
  • Reliable execution makes sudden surprises less likely

How it played out

ABT: the 13% growth thesis missed

Lyra published ABT at $101.85 as a short-term defensive rebound idea, with 13% expected growth and a $115.09 target. The thesis pointed to steady demand for medical and nutrition products, fresh analyst attention, a cheaper price after the pullback, and reliable execution.

ABT peaked at $103.84 on April 8, a 1.9% gain. It never reached the target. By July 6, the shares had fallen to $95.63, below both the publication price and the $99 to $103 entry zone. The thesis missed.

What happened during the window

On April 16, Abbott reported first-quarter sales growth of 7.8% and adjusted diluted earnings per share of $1.15. It projected full-year comparable sales growth of 6.5% to 7.5%.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABT signals